Cytokine storms force Mirna to shutter a trial; Artios gathers $33M for cancer drug work
A series of severe cases of cytokine release syndrome forced Austin, TX-based Mirna Therapeutics to shut down a Phase I study of its lead …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
